

Panther Fusion® Respiratory Assays

- A flexible, fully automated, modular approach to respiratory testing.

Symptoms alone don't tell the story. Panther Fusion respiratory assays provide flexibility for you to choose which common pathogens to test for with a single patient sample.

Accurate Diagnosis of Respiratory Tract Infections Improves Patient Care and Helps Decrease Costs²

- Helps ensure that patients receive timely and appropriate antiviral treatment for influenza and COVID-19.
- Helps reduce the potential for further development of antimicrobial resistance due to antibiotics.²
- Provides valuable information to public health authorities regarding which viruses are circulating in the community.¹
- Aids infection control personnel in determining the appropriate measures needed to minimize the spread of nosocomial infections.²

Seasonality of Respiratory Viruses May Impact:



Staffing



Testing volumes and associated workflows



Turn-around times



Flexible, Scalable, Respiratory Testing

With a modular respiratory testing platform, laboratories can prepare for and test for analytes based on seasonality, patient populations, and local prevalence during respiratory season and surges.

Respiratory viruses are responsible for a wide range of infections that can be particularly severe in young, immunocompromised, and elderly patients. Frequent causes include COVID-19, the common cold, and influenza. Many pathogens have overlapping and non-specific presentations, necessitating testing to detect and differentiate respiratory illnesses.

Fully Automate Any Combination and Volume of Respiratory Assays

With Panther Fusion Respiratory assays, you have the power to choose from a single sample.



- Flu A/B/RSV
- AdV/hMPV/RV
- Paraflu
- SARS-CoV-2/Flu A/B/RSV

- Choose from any combination of respiratory assays and process from a single patient sample.
- Offer flexible testing algorithms to improve provider and patient satisfaction.
- React to the unpredictable volumes of respiratory testing with scalable automation (up to 1,000 samples in 24 hours).
- Streamline workflows with fully-automated processing, and random and continuous access for sample and reagent loading.
- Minimize waste and maximize walk away time with ready-to-use reagents with 60-day on-board stability.
- Control costs by only running the assays needed, utilizing a flexible approach to testing.

Simplified Workflow on a Fully Automated Platform



References: 1. CDC. Influenza (Flu) Treatment. <https://www.cdc.gov/flu/treatment/index.html>. Last reviewed April 22, 2019. Accessed August 21, 2019. 2. Kahn JS. Epidemiology of Human Metapneumovirus. *Clin Microbiol Rev*. 2006;19(3):546-557. doi:10.1128/CMR.00014-06 3. Juretschko S. Confronting the challenges of influenza-like illness. *MLO*. Published October 24, 2017. <https://www.mlo-online.com/continuing-education/article/13009287/confronting-the-challenges-of-influenza-like-illness>.

SS-00682-001 Rev. 003 © 2023 Hologic, Inc. All rights reserved. Hologic, Panther Fusion, RespDirect and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com.